These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8694666)

  • 1. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
    Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
    Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
    Anand SS; Bates S; Ginsberg JS; Levine M; Buller H; Prins M; Haley S; Kearon C; Hirsh J; Gent M
    Arch Intern Med; 1999 Sep; 159(17):2029-32. PubMed ID: 10510988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.
    Hull RD; Raskob GE; Rosenbloom D; Lemaire J; Pineo GF; Baylis B; Ginsberg JS; Panju AA; Brill-Edwards P; Brant R
    Arch Intern Med; 1992 Aug; 152(8):1589-95. PubMed ID: 1497392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A standard heparin nomogram for the management of heparin therapy.
    Cruickshank MK; Levine MN; Hirsh J; Roberts R; Siguenza M
    Arch Intern Med; 1991 Feb; 151(2):333-7. PubMed ID: 1789820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.
    Hull RD; Raskob GE; Hirsh J; Jay RM; Leclerc JR; Geerts WH; Rosenbloom D; Sackett DL; Anderson C; Harrison L
    N Engl J Med; 1986 Oct; 315(18):1109-14. PubMed ID: 3531862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service.
    Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S
    Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.
    Legnani C; Mattarozzi S; Cini M; Cosmi B; Favaretto E; Palareti G
    Br J Haematol; 2006 Jul; 134(2):227-32. PubMed ID: 16846482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
    Prandoni P; Carnovali M; Marchiori A;
    Arch Intern Med; 2004 May; 164(10):1077-83. PubMed ID: 15159264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Nov; 157(20):2317-21. PubMed ID: 9361572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriate use of heparin. Empiric vs nomogram-based dosing.
    Gunnarsson PS; Sawyer WT; Montague D; Williams ML; Dupuis RE; Caiola SM
    Arch Intern Med; 1995 Mar; 155(5):526-32. PubMed ID: 7864708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical follow-up in 265 patients with deep venous thrombosis initially treated with either unfractionated heparin or dalteparin: a retrospective analysis.
    Holmström M; Aberg W; Lockner D; Paul C
    Thromb Haemost; 1999 Oct; 82(4):1222-6. PubMed ID: 10544902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time.
    Groce JB; Gal P; Douglas JB; Steuterman MC
    Clin Pharm; 1987 Mar; 6(3):216-22. PubMed ID: 3665377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements.
    White RH; Zhou H; Woo L; Mungall D
    Arch Intern Med; 1997 Nov; 157(21):2468-72. PubMed ID: 9385298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.